Get started
Author

Irina Surovtsova

Observed names: I Surovtsova, I. Surovtsova, Surovtsova, I.
ORCID: 0009-0003-4263-6250
Observed ORCID: 0009-0003-4263-6250
OpenAlex ID: A5048671973
Effects of compliance mismatch on blood flow in an artery with endovascular prosthesis
2004 · Irina Surovtsova · Journal of Biomechanics · 34
SYCAMORE—a systems biology computational analysis and modeling research environment
2008 · Andreas Weidemann, Stefan Richter, et al. · Bioinformatics · 30
Accessible methods for the dynamic time-scale decomposition of biochemical systems
2009 · Irina Surovtsova, Natalia Simus, et al. · Bioinformatics · 29
PDF
Simplification of biochemical models: a general approach based on the analysis of the impact of individual species and reactions on the systems dynamics
2012 · Irina Surovtsova, Natalia Simus, et al. · BMC Systems Biology · 23
PDF
Approaches to Complexity Reduction in a Systems Biology Research Environment (SYCAMORE)
2006 · Irina Surovtsova, Sven Sahle, et al. · Winter Simulation Conference · 14
Oncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study
2024 · André Pfob, Daria B. Kokh, et al. · Annals of Surgical Oncology · 10
Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort
2023 · Andreas Teufel, Isaac Rodriguez, et al. · Journal of Gastrointestinal and Liver Diseases · 10
PDF
Ca2+ dynamics correlates with phenotype and function in primary human neutrophils
2013 · Katrin Hübner, Irina Surovtsova, et al. · Biophysical Chemistry · 10
Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
2025 · Irina Surovtsova, Felix J. F. Herth, et al. · Pulmonology · 8
PDF
Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry
2024 · Jasmin Schuhbaur, Irina Surovtsova, et al. · BMC Cancer · 5
PDF
Inzidenz, Behandlung und Prognose des Prostatakarzinoms in Baden-Württemberg: Analyse anhand von Krebsregisterdaten
2024 · Thomas Stefan Worst, Irina Surovtsova, et al. · Die Urologie · 4
PDF
Use of chemotherapy and loco‐regional therapy in stage IA triple‐negative breast cancer and their association with oncologic outcomes: A cancer registry study
2024 · André Pfob, Irina Surovtsova, et al. · International Journal of Cancer · 3
PDF
Sebaceous Carcinoma: A Retrospective Multicenter Analysis of 213 Cases
2026 · Sebastian A. Wohlfeil, Jochen S. Utikal, et al. · Cancers · 1
PDF
Präzisionsonkologie in der Versorgungsrealität am Beispiel des Kolonkarzinoms
2023 · Irina Surovtsova, Petra Neuser, et al. · Die Onkologie · 1
Fluid Flows and Free Boundaries
2007 · B. Schweizer, S. Bodea, et al. · Springer eBooks · 1
151P When LLMs disagree: A cross-model strategy for scalable biomarker extraction from pathology reports
2026 · D. Kokh, I. Surovtsova, et al. · ESMO Real World Data and Digital Oncology
364P Beyond treatment assignment: Evaluating longitudinal oncology strategies using real-world cancer registry data
2026 · I. Surovtsova, P. Morakis · ESMO Real World Data and Digital Oncology
MO16.03: Sleeve Resection vs Pneumonectomy in NSCLC: Survival Benefit by Age, Nodal Status, and Resection Completeness
2026 · T. Schneider, I. Surovtsova, et al. · Journal of Thoracic Oncology
160P Lymphadenectomy in clinically node-negative ovarian cancer (FIGO I-III): A population-based analysis from the Baden-Wuerttemberg Cancer Registry
2026 · H. Endres, I. Surovtsova, et al. · ESMO Open
PDF
Real-World Emulation of Landmark Lung Cancer Trials: A Registry-Based Reconstruction of KN189, KN407, IMpower133, and PACIFIC
2026 · Irina Surovtsova, Wilfried E. E. Eberhardt, et al. · Cancers
474P Real-world outcomes of first-line endocrine therapy with or without CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: A cancer registry study
2026 · I. Surovtsova, P. Morakis · ESMO Open
2692 Real-World Evidence on Fractionation and Survival in Breast Cancer with an Indication for Nodal Irradiation
2026 · Irina Surovtsova, Markus Schirmer, et al. · Radiotherapy and Oncology
312P Real-world treatment landscape of stage III NSCLC: Comparing cisplatin and carboplatin in curative-intent therapy
2026 · W.E.E. Eberhardt, I. Surovtsova, et al. · ESMO Open
PDF
437P Immunotherapy in ES-SCLC: Real-world impact of atezolizumab/durvalumab, radiotherapy, and metastatic burden across ECOG 0-2 patients
2026 · I. Surovtsova, W.E.E. Eberhardt, et al. · ESMO Open
PDF
55P Impact of KRAS/TP53 and KEAP1/STK11 co-mutations on immune checkpoint inhibitor outcomes for metastatic NSCLC patients: Insights from real-world data
2026 · D. Kokh, I. Surovtsova, et al. · ESMO Open
PDF
Works count: 53
Citation count: 183
H-index: 8
I10-index: 8
Year
Topic
Type